Recent Updates
Recently added Catalysts
ELVN Positive Sentiment

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Key Takeaway: Enliven Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will be webcast live, allowing investors to access the discussion online. Enliven focuses on developing small molecule therapeutics aimed at improving patient outcomes.
Price reaction · baseline $29.28 (2026-02-25 close) · hit after-hours · 1 other ELVN headline(s) in the window, move may be shared
day 0 close · peak
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enliven Therapeutics is actively participating in a major healthcare conference.
  • The company is focused on developing innovative small molecule therapeutics.
  • The webcast will be accessible for 90 days, enhancing investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+259%
120-day peak, hindsight
Typical move
16.2%
average across 2 past catalysts
Cash runway
~144 mo
Minimal dilution risk
Lead asset
ELVN-002
Phase 1 · HER2-positive Breast Cancer

Full Press Release Details

BOULDER, Colo.,Feb. 25, 2026/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website athttps://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Enliven Therapeutics

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. To learn more, visitwww.enliventherapeutics.comand connect with us onLinkedInandX.

Frequently Asked Questions

When will Enliven Therapeutics present at the conference?

Enliven Therapeutics will present on March 3, 2026, at 10:30 a.m. ET.

How can I access the webcast of the event?

The webcast can be accessed through the investor relations section of Enliven's website.

What is the focus of Enliven Therapeutics?

Enliven Therapeutics focuses on developing small molecule therapeutics for better patient outcomes.

Will the webcast be available after the live event?

Yes, the webcast will be archived for 90 days after the live event.

Last updated: Feb 25, 2026